Related references
Note: Only part of the references are listed.Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features
J. Bellmunt et al.
ANNALS OF ONCOLOGY (2008)
The changing pattern of kidney cancer incidence and mortality in Europe
Fabio Levi et al.
BJU INTERNATIONAL (2008)
Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma
Robert J. Motzer et al.
CANCER (2008)
Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer
Philipp C. Manegold et al.
CLINICAL CANCER RESEARCH (2008)
Update on the medical treatment of metastatic renal cell carcinoma
Alain Ravaud et al.
EUROPEAN UROLOGY (2008)
Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma
Naeem Bhojani et al.
EUROPEAN UROLOGY (2008)
Everolimus:: an update on the mechanism of action, pharmacokinetics and recent clinical trials
Ana I. Sanchez-Fructuoso
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2008)
Experimental therapy for advanced renal cell carcinoma
Thomas E. Hutson et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Sunitinib (SUTENT®) for the treatment of metastatic renal cell carcinoma
Thomas E. Hutson
EXPERT REVIEW OF ANTICANCER THERAPY (2008)
Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data
Chiaki Tanaka et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma:: A randomized phase III clinical trial
Alain Ravaud et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Outcome After Surgical Resections of Recurrent Chest Wall Sarcomas
Michael W. Wouters et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC)
R. C. Whorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC)
R. A. Figlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: Results of a phase II study
James C. Yao et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors
Anne O'Donnell et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies
Thomas E. Hutson et al.
ONCOLOGIST (2008)
Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis
Hendrik Seeliger et al.
CANCER AND METASTASIS REVIEWS (2007)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
Identification of everolimus metabolite patterns in trough blood samples of kidney transplant patients
Tobin Strom et al.
THERAPEUTIC DRUG MONITORING (2007)
Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma
Daniel Cho et al.
CLINICAL GENITOURINARY CANCER (2007)
Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer
Jared A. Gollob et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy
Toni K. Choueiri et al.
CANCER (2007)
Prognostic relevance of the mTOR pathway in renal cell carcinoma - Implications for molecular patient selection for targeted therapy
Allan J. Pantuck et al.
CANCER (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Recent advances in the therapy of renal cancer
Guru Sonpavde et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: Combining surgery and systemic therapies to improve patient outcome
Christopher G. Wood
CLINICAL CANCER RESEARCH (2007)
Cytoreductive nephrectomy for metastatic renal cell carcinoma: Is it still imperative in the era of targeted therapy?
Allan J. Pantuck et al.
CLINICAL CANCER RESEARCH (2007)
The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer
Daniel Cho et al.
CLINICAL CANCER RESEARCH (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Treatment options in renal cell carcinoma: past, present and future
S. Oudard et al.
ANNALS OF ONCOLOGY (2007)
Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy
Katja Keller et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2006)
Sunitinib in patients with metastatic renal cell carcinoma
Robert J. Motzer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Patterns of pulmonary complications associated with sirolimus
Prashant N. Chhajed et al.
RESPIRATION (2006)
Global cancer statistics, 2002
DM Parkin et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2005)
Cytoreductive nephrectomy in patients with metastatic renal cancer: A combined analysis
RC Flanigan et al.
JOURNAL OF UROLOGY (2004)
Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells
A Boulay et al.
CANCER RESEARCH (2004)
Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
